New insider activity at Jasper Therapeutics ( (JSPR) ) has taken place on September 24, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant show of confidence in Jasper Therapeutics, key figures within the company have made substantial stock purchases. Director Judith Anne Shizuru, Director Thomas Wiggans, and President & CEO Ron Martell each acquired 41,000 shares, with each transaction valued at $99,630. Additionally, Director Svetlana Lucas purchased 20,000 shares for $48,600. These strategic investments underscore the leadership’s strong belief in the company’s future prospects.
Recent Updates on JSPR stock
In the last 24 hours, Jasper Therapeutics has been in the spotlight due to several key developments affecting its stock. Citizens JMP lowered the price target for Jasper Therapeutics from $12 to $6, maintaining an Outperform rating, following the company’s announcement of early findings from its BEACON study investigation. The study’s confounding results were attributed to issues at clinical sites or with enrolled patients, rather than drug manufacturing or distribution. Additionally, Jasper announced a $30 million public offering, aimed at extending its financial runway and supporting its briquilimab development programs. This offering is seen as a positive move to remove financial overhangs. Meanwhile, UBS also adjusted its price target for Jasper, citing uncertainties in the BEACON study and drug development timelines. Despite these challenges, Jasper’s strategic focus and promising clinical data continue to drive some positive analyst sentiment.
Spark’s Take on JSPR Stock
According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.
Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.
To see Spark’s full report on JSPR stock, click here.
More about Jasper Therapeutics
YTD Price Performance: -88.62%
Average Trading Volume: 643,061
Technical Sentiment Signal: Sell
Current Market Cap: $41.28M